Rapport Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 58
- Market Cap
- $746.1M
- Introduction
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
Inductive Bio Secures $25M Series A to Revolutionize Small Molecule Drug Discovery with AI
Inductive Bio has raised $25M in Series A funding led by Obvious Ventures to accelerate its AI-driven approach to small molecule drug discovery, focusing on predicting ADMET properties before synthesis.
Rapport Therapeutics' RAP-219 Shows Promise in Phase 1 Trials for CNS Disorders
Rapport Therapeutics' RAP-219 achieved target receptor occupancy within five days, supporting its potential for treating CNS disorders.
Rapport Therapeutics' RAP-219 Shows Promise in Focal Epilepsy with Novel Biomarker Approach
Rapport Therapeutics presents data linking reductions in long episode (LE) frequency to clinical seizure reduction in focal epilepsy.
FDA Updates: Clinical Hold on Rapport's RAP-219 for DPNP, Phase 2 Trial for Mivelsiran in CAA, and Review of Ataluren Resubmission
The FDA has placed a clinical hold on Rapport Therapeutics' RAP-219 IND application for diabetic peripheral neuropathic pain (DPNP) due to protocol design concerns.
Rapport Therapeutics Provides Update on RAP-219 Clinical Trials and Financial Results
Rapport Therapeutics is advancing RAP-219, a precision medicine for CNS disorders, with Phase 2a trial in focal epilepsy on track for mid-2025 data.
FDA Halts Rapport Therapeutics' RAP-219 Trial for Diabetic Neuropathic Pain
The FDA has placed a clinical hold on Rapport Therapeutics' IND application for RAP-219, an investigational therapy for diabetic peripheral neuropathic pain (DPNP).
Rapport Therapeutics Provides Update on RAP-219 Clinical Programs and Financial Status
Rapport Therapeutics is advancing RAP-219 in Phase 2a trials for focal epilepsy, with topline data expected in mid-2025, showing commitment to CNS disorder treatments.
Rapport Therapeutics Advances RAP-219 Clinical Trials for CNS Disorders
Rapport Therapeutics is progressing with Phase 2a trial of RAP-219 in focal epilepsy, with topline data expected in mid-2025.
Rapport Therapeutics Gains Buy Recommendation Based on RAP Platform and RAP-219 Potential
Rapport Therapeutics receives a Buy rating from JonesTrading, driven by its innovative RAP platform targeting central nervous system disorders.